GEMP - Gemplus International

0.3
0.300   100.000%

Share volume: 0
Last Updated: 12-30-2019

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.30
P/E Ratio 
N/A
DAY RANGE
$0.30 - $0.30
EPS 
-$0.97
52 WEEK RANGE
$0.24 - $1.48
52 WEEK CHANGE
-$62.96
MARKET CAP 
4.462 M
YIELD 
N/A
SHARES OUTSTANDING 
14.872 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$10,283,572
AVERAGE 10 VOLUME 
$78,503
AVERAGE 30 VOLUME 
$148,676
Company detail
CEO: Steven R. Gullans
Region: US
Website: http://www.gemphire.com
Employees: 9
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry:
Sector:

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.

Recent news